Alnylam touts label expansion for rare oxalate disease
Almost two years after securing its third drug approval, Alnylam is touting an expanded label for Oxlumo.
The company put out word on Thursday night …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
